Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 4Tumor-Agnostic 3CNS 3Thoracic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Melanoma 5Lung Neoplasms 3Urinary Bladder Neoplasms 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Esophageal Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Skin Neoplasms 1Sarcoma 1Neoplasms, Squamous Cell 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Chondrosarcoma 1Carcinoma, Transitional Cell 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

pembrolizumab 61Carboplatin 44Pemetrexed 31Paclitaxel 31Docetaxel 31Cisplatin 27Gemcitabine 24Nivolumab 23Erlotinib Hydrochloride 21Bevacizumab 18Ipilimumab 11osimertinib 10Drug Therapy 10atezolizumab 9Radiosurgery 9Cyclophosphamide 9Cetuximab 9Blood Specimen Collection 9durvalumab 8cemiplimab 8Radiotherapy 8budigalimab 7Fluorouracil 7Dexamethasone 7trametinib 6fludarabine 6dostarlimab 6avelumab 6Taxes 6130-nm albumin-bound paclitaxel 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × poly ICLC × Thoracic × Clear all
NCT02661100 2016-12-07

A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients

Case Comprehensive Cancer Center

Phase 1/2 Withdrawn
DermatologicOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Mesothelioma, Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡